A bacterial infection proved resistant to all available treatments, leading a group of researchers to turn to artificial intelligence to design viruses capable of specifically targeting that bacterium. Now, for the first time—according to those leading the project—viruses developed with the aid of AI have been administered to a human patient.

The experiment was announced by the U.S. startup , which developed an artificial intelligence model called Omnii-1. But why use viruses to fight an infection? The answer lies in bacteriophages—viruses that can infect and destroy bacteria without directly attacking human cells. This approach has been studied for decades as an alternative for dealing with antibiotic-resistant infections.

The persistent challenge has always been finding bacteriophages capable of identifying and destroying the specific bacterial strain responsible for a given infection; this is where artificial intelligence came into play. The researchers used Omnii-1 to design genetic modifications for viruses, aiming to create versions capable of combating a resistant strain of the bacterium *Escherichia coli*. After producing and testing various variants in the laboratory, the team achieved highly promising results.

According to the company, a combination containing viruses designed by AI succeeded in eliminating the bacteria isolated from the patient during in vitro tests. Based on this data, the experimental treatment received special emergency use authorization from the FDA and was ultimately administered to the patient; however, a crucial piece of information has yet to be disclosed.

The company did not reveal whether the patient’s condition improved or if the infection was completely eradicated from their body; therefore, it is not yet possible to speak of a confirmed cure. Furthermore, the results must undergo independent scientific evaluation through peer review. Even so, the experiment opens a vital door: the use of artificial intelligence to accelerate the development of personalized biological treatments for complex, multi-drug-resistant infections.

If this technology proves safe and effective in larger clinical trials, it could hasten the search for viable alternatives to conventional antibiotics. For now, while the viruses performed successfully in laboratory tests, it remains to be seen whether they can achieve the same results—with complete safety—within the human body.